Literature DB >> 28233110

Subacute invasive pulmonary aspergillosis as a rare cause of pneumothorax in immunocompetent patient: brief report.

Tatjana Adzic Vukicevic1,2, Aleksandra Dudvarski-Ilic3,4, Vladimir Zugic3,4, Goran Stevanovic3,5, Salvatore Rubino6, Aleksandra Barac5.   

Abstract

Subacute invasive pulmonary aspergillosis (IPA) represents a form of chronic pulmonary aspergillosis which affects immunocompetent individuals or mildly immunocompromised persons with underlying pulmonary disease. Pneumothorax can be a rare complication of subacute IPA due to a leakage of air from an air-filled lung cavitation into the pleural space. Herein, we report rare and unusual case of pneumothorax in a patient with pulmonary cavity infection. A 40-year-old woman was admitted to thoracic surgery due to complete pneumothorax of the left lung. She was active smoker with untreated chronic obstructive pulmonary disease (COPD). After thoracic drainage multiple cavity forms in the both lungs were noticed. Galactomannan antigen was positive in bronchoalveolar lavage as well as culture of Aspergillus fumigatus. Antifungal treatment by voriconazole was started and continued during 6 months with a favorable outcome. This case highlights that subacute IPA is a diagnose that should be considered in patients with end-stage COPD, low body mass index, or patient who developed pneumothorax. The results of our case show that voriconazole is a safe and effective treatment as primary or salvage therapy in subacute forms of IPA, irrespective of the immunological status of the patients.

Entities:  

Keywords:  Aspergillus fumigatus; COPD; Pneumothorax; Subacute invasive pulmonary aspergillosis; Voriconazole

Mesh:

Substances:

Year:  2017        PMID: 28233110     DOI: 10.1007/s15010-017-0994-3

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

1.  Subacute Invasive Pulmonary Aspergillosis Associated with Ankylosing Spondylitis.

Authors:  Amy Houghton Attaway; Frank Jacono; Robert Gilkeson; Jihane Abdelmassih Faress
Journal:  Am J Respir Crit Care Med       Date:  2016-03-01       Impact factor: 21.405

2.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

3.  Unusual forms of subacute invasive pulmonary aspergillosis in patients with solid tumors.

Authors:  M Peghin; I Ruiz-Camps; C Garcia-Vidal; C Cervera; J Andreu; M Martin; J Gavaldá; C Gudiol; A Moreno; E Felip; A Pahissa
Journal:  J Infect       Date:  2014-05-15       Impact factor: 6.072

4.  Global burden of chronic pulmonary aspergillosis complicating sarcoidosis.

Authors:  David W Denning; Alex Pleuvry; Donald C Cole
Journal:  Eur Respir J       Date:  2012-06-27       Impact factor: 16.671

5.  Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management.

Authors:  David W Denning; Jacques Cadranel; Catherine Beigelman-Aubry; Florence Ader; Arunaloke Chakrabarti; Stijn Blot; Andrew J Ullmann; George Dimopoulos; Christoph Lange
Journal:  Eur Respir J       Date:  2016-01       Impact factor: 16.671

6.  Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.

Authors:  Raoul Herbrecht; David W Denning; Thomas F Patterson; John E Bennett; Reginald E Greene; Jörg-W Oestmann; Winfried V Kern; Kieren A Marr; Patricia Ribaud; Olivier Lortholary; Richard Sylvester; Robert H Rubin; John R Wingard; Paul Stark; Christine Durand; Denis Caillot; Eckhard Thiel; Pranatharthi H Chandrasekar; Michael R Hodges; Haran T Schlamm; Peter F Troke; Ben de Pauw
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

7.  Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett
Journal:  Clin Infect Dis       Date:  2016-06-29       Impact factor: 9.079

8.  The utility of galactomannan antigen in the bronchial washing and serum for diagnosing pulmonary aspergillosis.

Authors:  Yuta Kono; Kenji Tsushima; Koichi Yamaguchi; Nao Kurita; Seiko Soeda; Akahito Fujiwara; Shinya Sugiyama; Yuki Togashi; Satoshi Kasagi; Masako To; Yasuo To; Yasuhiro Setoguchi
Journal:  Respir Med       Date:  2013-04-28       Impact factor: 3.415

9.  Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial.

Authors:  J Cadranel; B Philippe; C Hennequin; A Bergeron; E Bergot; A Bourdin; V Cottin; T Jeanfaivre; C Godet; M Pineau; P Germaud
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-11       Impact factor: 3.267

10.  Pneumothorax: a rare presentation of pulmonary mycetoma.

Authors:  Prem Parkash Gupta; Sanjay Fotedar; Dipti Agarwal; Sarita Magu; Kuldeep Saini
Journal:  Ann Thorac Med       Date:  2007-10       Impact factor: 2.219

  10 in total
  1 in total

Review 1.  Complications of chronic necrotizing pulmonary aspergillosis: review of published case reports.

Authors:  Aleksandra Barac; Tatjana Adzic Vukicevic; Aleksandra Dudvarski Ilic; Salvatore Rubino; Vladimir Zugic; Goran Stevanovic
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2017-04-13       Impact factor: 1.846

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.